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Summary 30 
Background A single drug, praziquantel, is available for the treatment of 31 
Opisthorchis viverrini infections. In vivo studies point to an activity of mefloquine, 32 
artesunate and tribendimidine against this liver fluke.  33 
Methods In a randomized, exploratory open-label trial, the efficacy (cure rate 34 
[CR] and egg reduction rate [ERR]) and safety of mefloquine (25 mg/kg), 35 
artesunate (10 mg/kg as 3 split doses within 12 h), mefloquine-artesunate (100 36 
mg artesunate plus 250 mg mefloquine once daily for 3 consecutive days), and 37 
tribendimidine (200 or 400 mg single dose) compared to praziquantel (75 mg/kg 38 
in 2 divided doses) were studied against O. viverrini in 125 schoolchildren in 39 
Attapeu Province, Lao PDR. 40 
Results Tribendimidine and praziquantel achieved CRs of 70.4% and 56.0%, 41 
respectively on the basis of intention to treat analysis. The corresponding ERRs 42 
were 99.3% and 98.4%. No or only very moderate effects were observed with 43 
mefloquine, artesunate and mefloquine-artesunate against O. viverrini (CRs: 0-44 
4.2% and ERRs 30.2-41.3%). Children treated with tribendimidine experienced 45 
only mild and transient adverse events such as, headache, vertigo, nausea and 46 
fatigue. The most frequent adverse events, many of which were serious, were 47 
dizziness, nausea, vertigo, vomiting and headache were mainly experienced 48 
among those patients treated with mefloquine and mefloquine-artesunate.  49 
Interpretation Tribendimidine is not only efficacious against various intestinal 50 
nematodes but also against O. viverrini. Large-scale clinical trials are warranted 51 
once additional preclinical studies for drug registration outside China will have 52 
been completed.  53 
Funding Swiss National Science Foundation (project no. PPOOA-114941) and 54 
the University of Basel. 55 
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Introduction 56 
Opisthorchiasis is a neglected tropical disease caused by the liver fluke 57 
Opisthorchis viverrini, which affects the poorest people in Northeastern parts of 58 
Thailand, Lao People’s Democratic Republic (Lao PDR), Cambodia and 59 
Vietnam.1,2 An estimated 67.3 million people are at risk and 9 million are 60 
infected.1 In Lao PDR, the highest prevalence rates (50% in school children and 61 
up to 90% in adults) of O. viverrini have been reported from villages adjacent to 62 
the Mekong River, particularly in the Southern and central provinces.3,4 Though 63 
most human opisthorchiasis cases are asymptomatic, chronic infection with 64 
O. viverrini can cause obstructive jaundice, ascending cholangitis, cholecystitis, 65 
gallstones, hepatomegaly and an enhanced risk for cholangiocarcinoma.5-7 66 
Cholangiocarcinoma is a serious and fatal complication, incurable in the 67 
advanced stage, hence early diagnosis and treatment is imperative.6,8-10 68 
Morbidity control through periodic treatment with praziquantel is the key 69 
control strategy for opisthorchiasis.11,12 Praziquantel is the only available drug so 70 
that if resistance does develop to it, there will be no active drug left unless other 71 
treatments are developed. We have recently reported that the antimalarials 72 
artemether, artesunate (2 semisynthetic derivatives of artemisinin), mefloquine 73 
and the Chinese anthelminthic drug tribendimidine have interesting 74 
opisthorchicidal properties in rodents.13,14 For example, administration of 75 
artesunate and artemether at a dose of 400 mg/kg to O. viverrini-infected 76 
hamsters resulted in worm burden reductions of 78.4% and 65.5%, 77 
respectively.13,14 Similarly, high worm burden reductions were reported with a 78 
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single 300-mg/kg oral dose of mefloquine against juvenile and adult O. viverrini in 79 
vivo.15 Finally, a 400 mg/kg oral dose of tribendimidine achieved a worm burden 80 
reduction of 95.7% in O. viverrini infected hamsters.14 81 
The aim of the present study was to assess the efficacy and safety of 82 
mefloquine, artesunate, mefloquine-artesunate, tribendimidine compared to the 83 
treatment of choice, praziquantel in patients with a parasitologically confirmed 84 
O. viverrini infection. 85 
 86 
Patients and methods 87 
Study site and population 88 
The study was carried out in the Saysetha district, Attapeu province, Lao 89 
PDR, from February to April 2010. Attapeu Province has a total area of 10,320 90 
km2 and is the most south-easterly province of Lao PDR. A previous study 91 
showed O. viverrini prevalence rates of 21% among primary school children in 92 
Attapeu.4 The province has approximately 93,000 inhabitants. The majority 93 
belong to the ethnic group of Lao Theung and is mainly engaged in subsistence 94 
rice cultivation.16 The Saysetha upper and lower secondary school was selected 95 
for our study, where a total of 957 secondary schoolchildren were enrolled during 96 
the academic year 2008-2009. A preliminary survey showed that in this school 97 
the O. viverrini infection prevalence was higher than 50% (personal 98 
communication Mr. Thongsom, Provincial Hospital Attapeu). 99 
 100 
Study design 101 
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The study was designed as a randomized, exploratory open-label trial to 102 
assess the efficacy and safety of mefloquine, artesunate, mefloquine-artesunate 103 
and tribendimidine against O. viverrini infection among schoolchildren compared 104 
to the standard praziquantel treatment regimen. The sample size was based on a 105 
suggested sample size of 12 patients / group for proof-of-concept trials 106 
recommended by Julious.17,18 To account for drop outs we aimed at 20-25 107 
children per group. 108 
On day 21-22 post-treatment we assessed the cure rate [CR], defined as 109 
the percentage of the children excreting eggs before treatment but in whom no 110 
eggs were found when reexamined and egg reduction rate [ERR], defined as the 111 
group’s reduction of geometric mean [GM] egg output after treatment divided by 112 
the GM of the same patients pretreatment, multiplied by 100. 113 
 114 
Study procedures 115 
One week before the baseline screening survey, the National Institute of 116 
Public Health, Centre of Malaria, Parasitology and Entomology, Centre for 117 
Laboratory and Epidemiology, and the Provincial Department of Health and the 118 
Provincial Hospital of Attapeu, as well as the teachers were informed about the 119 
study objectives, procedures, benefits and potential risks. Overall, 214 120 
schoolchildren aged between 10 to 15 years were invited to participate and the 121 
children and parents were asked to provide written informed consent. From each 122 
consenting and participating child at least 2 stool samples were collected within 5 123 
consecutive days. Children with a parasitologically confirmed O. viverrini infection 124 
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(at least 2 of 4 slides positive), underwent a full clinical examination, including 125 
measurement of weight (using an electronic balance measuring to the nearest 126 
0.1 kg, and axillary temperature using battery-powered thermometers to the 127 
nearest 0.01°C). In addition, a finger prick blood sample was taken from each 128 
child for a rapid malaria test (Paracheck Pf®) and a urine sample from all 129 
females for pregnancy testing (Quick-Check® hCG pregnancy test). Clinical 130 
malaria was defined as fever (axillary temperatures ≥ 37.5°c) and parasitaemia ≥ 131 
100/microL.19 Exclusion criteria included (i) presence of clinical malaria, (ii) 132 
pregnancy, (iii) presence of any abnormal medical condition (iv) history of any 133 
acute or severe chronic disease, (v) psychiatric and neurological disorders, (vi) 134 
use of artesunate, artemether, any artemisinin-based combination chemotherapy 135 
(ACT), mefloquine, or any anthelminthic treatment within the past month, and (vii) 136 
weight below 20 kg. Consenting children, who met all study criteria, were 137 
randomly assigned to one of the 5 different treatments using a computer-138 
generated randomization code.  139 
 140 
Drugs and adverse events 141 
Mefloquine (Mephaquine® 250-mg/lactab) and mefloquine-artesunate 142 
(Artequin®) were the products of Mepha AG (Aesch, Switzerland). Artesunate 143 
(50-mg tablet) was kindly obtained from Dafra Pharma (Turnhout, Belgium). 144 
Tribendimidine (200-mg tablet) was the product of Shandong Xinhua 145 
Pharmaceutical Corporation. Tribendimidine is registered in China and the 146 
efficacy against soil-transmitted helminths and safety has been documented in 147 
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thousands of patients.20,21 Praziquantel (600-mg tablet) was purchased from 148 
Inresa (Bartenheim, France). Mefloquine and mefloquine-artesunate were 149 
administered following the recommended malaria treatment schedules: 150 
mefloquine: 25 mg/kg single dose (body weight < 30 kg) or a split dose spaced 151 
by 6 hours at weights above 30 kg (e.g. at body weights 30-34 kg 2 lactabs were 152 
administered followed by 1 lactab 6 hours later) and mefloquine-artesunate: 1 153 
tablet of 100 mg artesunate and 1 lactab mefloquine 250 mg once daily for 3 154 
consecutive days. Mefloquine and praziquantel were administered to the nearest 155 
half tablet according to the calculate dose per kg of body weight. For artesunate 156 
a previously used malaria treatment schedule (10 mg/kg as 3 split doses within 157 
12 h) was used.22 Tribendimidine was given following the manufacturer’s 158 
instruction for the treatment of soil-transmitted helminth infections: 200 mg (age 159 
below 14 years) or 400 mg (age above 14 years) as a single dose. Finally, 160 
praziquantel was administered according to Lao national policies: 75 mg/kg in 2 161 
divided doses of 50 and 25 mg/kg spaced by 6 hours. All children received a 162 
biscuit and water before drug administration to improve tolerability and increase 163 
bioavailability.23 164 
Children were supervised for at least 3 hours after treatment and were 165 
asked to report any potential drug-related signs and symptoms at 24 h, 48 h, and 166 
120 h after the first dosing using a standardized questionnaire. A full clinical 167 
examination was performed by a study physician in case children reported 168 
adverse events and an appropriate treatment was given. The intensity of adverse 169 
events was graded as judged by study physicians (mild, moderate, severe, 170 
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serious or life-threatening). At the end of the study O. viverrini egg positive 171 
children enrolled in our study were treated with praziquantel (40 mg/kg). All 172 
schoolchildren received a single oral albendazole (400 mg) following Lao national 173 
scheme for mass drug administration  in Lao PDR.24,25 174 
 175 
Laboratory procedures 176 
Filled stool containers were collected from children between 08:00 and 177 
09:00 am and replaced with empty containers to obtain at least 2 stool samples 178 
from each child within a period of 5 days. Stool containers were then taken to the 179 
laboratory at the provincial hospital. From each stool sample 2 Kato-Katz (KK) 180 
thick smears using the standard 41.7 mg template were prepared and 181 
quantitatively examined under a light microscope at a x 100 magnification for 182 
helminth eggs. Each KK slide was read within 30 to 45 minutes after preparation. 183 
The number of O. viverrini eggs and soil-transmitted helminths eggs, i.e. Ascaris 184 
lumbricoides, hookworm, Trichuris trichiura and Taenia spp., were counted and 185 
recorded for each parasite species separately. 10% of the slides were 186 
reexamined for quality control by a senior microscopist. In addition, four samples 187 
(2 pre- plus 2 post-treatment) of stools were preserved in 10 ml sodium acetate-188 
acetic acid-formalin (SAF) solution which contained exactly 500 mg of stool for 189 
examination with the formalin-ether concentration technique (FECT), 190 
respectively, which allows differentiating between O. viverrini and minute 191 
intestinal fluke infections (MIF).26,27 Specimens of patients, for which pre- and 192 
post treatment samples could be preserved (per protocol analysis) were shipped 193 
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to a referral laboratory, at the Khon Kaen University, Thailand. For the FECT 194 
analysis the sample was centrifuged, and the sediment analyzed using a light 195 
microscope at 40 x and 100 x magnifications.28  196 
 197 
Ethical approval and consent  198 
The study was approved by the institutional research commission of the Swiss 199 
Tropical and Public Health Institute (Swiss TPH, Basel, Switzerland) and the 200 
Ethics Committee of Basel (no 209/09). Ethical clearance was obtained from the 201 
National Ethics Committee (NEC), Ministry of Health (MOH) in Vientiane 202 
(no279/NECHR). The trial was registered with Current Controlled Trials, 203 
ISRCTN23425032. Permission for field work was provided by the MOH, the 204 
Provincial Health Department and the Provincial and District Education Office 205 
(DHO). Written informed consent was obtained from the parents or legal 206 
caretakers of each child. In addition, we also informed the participants and their 207 
parents that tribendimidine is currently registered only in China, and as such 208 
considered to be an investigational drug in Laos. We explained risk and benefits 209 
on the consent form in Lao language. 210 
 211 
Data management and statistical analysis 212 
All data were double entered using EpiData version 3.1 (Epidata 213 
Association; Odense, Denmark). Statistical analyses were performed with STATA 214 
statistical software version 10.1 (Stata Corp., College Station, TX, USA). Efficacy 215 
and safety were evaluated with intention to treat and per protocol analyses. 216 
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Intention to treat was defined as an analysis based on the initial treatment intent 217 
and per protocol analysis was defined as children who completed the entire 218 
clinical trial. 219 
Descriptive statistics are presented as counts, percentages, means and 220 
standard deviations, as appropriate. Prevalence of O. viverrini was stratified 221 
according to the classification of infection intensities proposed by Maleewong et 222 
al.: light infections (1-999 eggs per gram of feces [epg]), moderate (1,000-9,999 223 
epg) and severe (epg >10,000).29 CR and ERR were assessed as efficacy 224 
outcomes. Logistic regression models were used to examine CRs of O. viverrini 225 
and hookworm among different treatment arms (comparison of odds of parasite 226 
clearance between treatment groups). Odds ratio of parasite clearance and 95% 227 
confidence intervals were reported. Negative binomial regression was applied to 228 
compare ERR between the numbers of O. viverrini eggs recovered in stool 229 
examination among mefloquine, artesunate, mefloquine-artesunate and 230 
tribendimidine compared to praziquantel. Egg reduction rate ratio (ERRR) and 231 
95% confidence interval were reported. 232 
Pearson’s x2 test was applied to compare the baseline binary 233 
characteristics and the proportion of the reported adverse events between the 234 
treatment arms. Statistical significance was estimated using a likelihood ratio 235 
test. Negative binominal models were fitted to compare the number of adverse 236 
events among the treatment groups. P-value below 5% was considered 237 
significant.  238 
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Results  239 
Baseline characteristics 240 
Of 214 schoolchildren screened with the Kato Katz method, 197 (92.1%) 241 
were O. viverrini positive (Figure 1). We excluded 72 children (36.5%) from the 242 
trial since they provided only a single stool sample (70 children), fever (1 child) 243 
and splenomegaly (1 child). 125 participants were randomly allocated to 5 244 
treatment arms and included in the intention-to-treat analysis. The groups were 245 
not equal-sized (24 children in the artesunate and artesunate-mefloquine 246 
treatment groups versus 27 children in the tribendimidine group) since two 247 
patients were erroneously assigned to the tribendimidine group, instead of the 248 
artesunate and mefloquine-artesunate treatment groups. Of the 125 participants, 249 
19 children (15.2%) were lost to follow-up at the end of study. Four stool samples 250 
(2 pre- plus 2 post-treatment) were available from 106 individuals (per protocol 251 
analyses).  252 
Table 1 summarizes the demographic and laboratory baseline 253 
characteristics of the study participants. All baseline characteristics of the 254 
treatment groups were similar except for a slightly higher number of males in the 255 
mefloquine treatment group, which was however not statistical significant (chi2, 256 
3.97; P=0.41). Overall 63 males and 62 females, mean age 13.4±1.4 years, were 257 
included in the study. The intensity of O. viverrini infections was mostly mild to 258 
moderate. Overall, O. viverrini GM egg counts ranged from 609.1 to 3917.7 epg. 259 
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The overall prevalence of A. lumbricoides, T. trichiura and Taenia spp was below 260 
16.0%, hence these parasites were not included in the efficacy evaluation. 261 
Hookworm infection rates ranged from 70.8% to 83.3%. Results of FECT 262 
confirmed the presence of an O. viverrini infection in all participants. The 263 
O. viverrini GM baseline egg counts obtained by FECT ranged from 82.5 to 639.0 264 
epg (n=106) (data not shown). In 2 and 9 patients co-infections with MIF or 265 
intestinal protozoa were recorded. 266 
Efficacy evaluation 267 
As presented in Table 2 according to intention to treat analysis the highest 268 
CR was observed for tribendimidine (70.4%) followed by praziquantel (56.0%). 269 
No statistically significant difference was observed between the CRs of 270 
tribendimidine and praziquantel (Egg reduction rate ratio 1.87; P= .29). None of 271 
the children receiving mefloquine was cured and very low CRs were calculated 272 
for artesunate (4.2%), and mefloquine-artesunate (4.2%). Both tribendimidine 273 
and praziquantel resulted in almost complete egg elimination with ERRs of 99.3% 274 
and 98.4% (Table 3: Egg reduction rate ratio 1.0; P= .98), respectively. By 275 
contrast, mefloquine, artesunate, and mefloquine-artesunate had significantly 276 
lower ERRs of 30.2, 31.5 and 41.3%, respectively (Table 3: P< .01), except for a 277 
combination mefloquine-artesunate   (Table 3: P= .08) 278 
 279 
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Results of the per protocol analysis (Kato Katz data) were similar to those 280 
of the intention-to-treat analysis. CRs of tribendimidine, praziquantel, mefloquine-281 
artesunate, artesunate and mefloquine were 79.2, 63.6, 6.0, 4.2 and 0%, 282 
respectively (Table 2). Again both tribendimidine and praziquantel resulted in 283 
ERRs >98.0%, while ERRs in the mefloquine, artesunate and mefloquine-284 
artesunate treatment groups were significantly lower (Table 3: P< .01), except for 285 
a combination mefloquine-artesunate (Table 3: P= .06). On the other hand, 286 
considering FECT analysis much higher CRs and ERRs were noted. CRs of 287 
tribendimidine, praziquantel, mefloquine-artesunate, artesunate and mefloquine 288 
were 95.8, 95.5, 47.1, 33.3 and 20.0%, respectively. The corresponding ERRs 289 
were 99.1, 99.0, 75.0, 60.0 and 71.0%. While no statistical significant difference 290 
was observed between CRs and ERRs of tribendimidine and praziquantel 291 
treatment (Table 3: P= .25 and .98, respectively) CRs and ERRs of the 292 
antimalarials were significantly lower (Table 3: P< .01), except for a combination 293 
mefloquine-artesunate   (Table 3: P= .14) 294 
Mefloquine, artesunate, mefloquine-artesunate and praziquantel had no 295 
effect against hookworms, whereas tribendimidine achieved CRs of 65.0% (both 296 
intention to treat and per protocol analysis) (P= .004). 297 
Safety evaluation 298 
Adverse events were assessed at 3, 24, 48 and 120 hours after the first 299 
dosing as summarized in Table 4. None of the symptoms were reported before 300 
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treatment. The majority of symptoms were reported to be mild 3 hours post-301 
treatment, then increased in severity and subsided 48 hours post-treatment. In 302 
total, 92 (73.6%) mild, 47 (37.6%) moderate, 23 (18.4%) severe and 12 (9.6%) 303 
serious adverse events were reported (Table 5). 120 hours after treatment 304 
children were re-examined by the same physicians. None of them reported any 305 
adverse event and all children resumed their normal activities. 306 
At least one adverse event was reported by 66.7, 74.0, 80.0, 88.0, and 307 
96.0% of patients from the artesunate, tribendimidine, praziquantel, mefloquine 308 
and mefloquine-artesunate treatment groups, respectively (Table 5). No 309 
statistically significant difference was observed in the frequency of any adverse 310 
event among the tribendimidine, praziquantel and artesunate treatment groups. 311 
Most reported symptoms in the tribendimidine treatment group were mild 312 
including headache (44.4%), vertigo (33.4%), nausea (33.4%) and fatigue 313 
(18.5%) (Table 4). The most common symptoms reported, vertigo and nausea, 314 
were significantly more often observed in children treated with mefloquine (P= 315 
.02 and P= .007, respectively) than in any other treatment group. Additionally, 316 
dizziness was more common in patients who received mefloquine (P= .02), and 317 
mefloquine-artesunate (P= .001) than in patients who were treated with 318 
praziquantel. Twelve children treated with mefloquine or mefloquine-artesunate 319 
experienced serious adverse events including dizziness, nausea, vertigo, 320 
vomiting and were transferred to the provincial and local hospital. These children 321 
received a full clinical examination and proper medical mitigation measures 322 
including parentheral transfusion, antiemetic drugs, paracetamol or oral 323 
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rehydration. The children were closely monitored and after 48 hours of 324 
hospitalization all children had recovered and could be been discharged. 325 
Discussion 326 
We evaluated the effectiveness and safety of the antimalarial drugs 327 
mefloquine, artesunate and mefloquine-artesunate and the Chinese broad 328 
spectrum anthelmintic drug tribendimidine in the treatment of O. viverrini patients. 329 
To our knowledge these drugs have not been studied to date against O. viverrini 330 
infections. It is interesting to note that another antimalarial drug, chloroquine was 331 
historically used for treating opistorchiasis; however, the CR and ERR were 332 
unsatisfactory.30 Praziquantel served as reference, since it is the drug of choice 333 
for the treatment of O. viverrini.25 Adverse events following praziquantel 334 
treatment are generally mild and transient, as confirmed in our study.31 A single 335 
dose of 40 mg/kg praziquantel is widely used for community mass drug 336 
administration (MDA) in Southeast Asia. In Laos, MDA was initially introduced in 337 
the 1980s in high risk areas, under the close collaboration the Ministry of Health 338 
and WHO.32 Since then the morbidity due to O. viverrini infections has declined 339 
considerable. In our study a split dose of 75 mg/kg praziquantel (75-mg/kg 340 
divided into two doses of 50 and 25-mg/kg) was used, which is recommended for 341 
individual treatment and is the most effective regimen.24 We observed only 342 
moderate CRs following praziquantel treatment in our study which contrasts to 343 
previous studies which observed CRs between 96 and 100%.33-35  344 
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It is encouraging that a single 200 or 400 mg oral dose of tribendimidine 345 
achieved higher cure and egg reduction rates than a double dose of praziquantel, 346 
though this finding was not statistically significant since only a small number of 347 
children was included in our exploratory study. Tribendimidine is an amidantel 348 
derivative, first discovered and developed in China.36 Preclinical and clinical 349 
studies have been launched to meet the international standard accepted by the 350 
FDA and European regulatory agencies, with the ultimate goal of gaining 351 
tribendimidine regulatory approvals for the treatment of soil-transmitted 352 
helminthiases outside of China and inclusion in the WHO’s Essential Medicines 353 
List. Tribendimidine has a broad spectrum of activity against intestinal nematodes 354 
(e.g. A. lumbricoides, Enterobius vermicularis and the hookworms).37 A recent 355 
study in China showed that single-dose oral tribendimidine was efficacious 356 
against A. lumbricoides and hookworm while showing promising activities against 357 
Strongyloides stercoralis and Taenia spp.38 The good efficacy of tribendimidine 358 
against hookworm infections was confirmed in our study. 359 
In contrast to recent laboratory findings, mefloquine, artesunate and a 360 
combination of mefloquine-artesunate showed no effect in the treatment of 361 
O. viverrini infections. In a recent proof-of-concept study against another 362 
trematode, Schistosoma haematobium in Côte d’Ivoire mefloquine and 363 
artesunate achieved similarly low CRs (21.0 and 25.0 %, respectively) however 364 
slightly higher ERRs (74.0 and 85.0%, respectively) were seen. Furthermore, 365 
promising results were observed with mefloquine-artesunate (CR: 61.0%, ERR 366 
>95.0%).17  367 
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We discriminated between O. viverrini infections and other common 368 
foodborne trematodes using FECT (Table 2). The results obtained with FECT 369 
confirmed the high efficacy of tribendimidine against O. viverrini. It is interesting 370 
to note that FECT yielded higher CRs of praziquantel and tribendimidine than the 371 
Kato Katz method, which might be explained by lower sensitivity of FECT 372 
technique compared to KK thick smears. Our findings are consistent with the 373 
study by Lovis and colleagues which demonstrated a lower sensitivity of FECT 374 
(49.4%) compared to one KK thick smear (62.3%).39 Conversely, the lower 375 
sensitivity of FECT in this study contrasts with results obtained from a study 376 
conducted in the southern part of Lao PDR,40 where FECT showed a sensitivity 377 
of 96.8% in the diagnosis of O. viverrini infections. It seems that the amount of 378 
stool used in FECT is not of primary importance. However, Sayasone and 379 
colleagues used the purging of patients as the reference “gold-standard” to 380 
calculate the validity of FECT.40 Interestingly, two previous studies conducted in 381 
Lao PDR 39,40 using the same diagnostic tools to differentiate O. viverrini from 382 
O. viverrini-like parasites demonstrated that O. viverrini often coexists with other 383 
foodborne trematodes including MIF, including Haplorchis taichui. In our study 384 
very few coinfections with MIF were detected.  385 
Children who were treated with praziquantel, artesunate and 386 
tribendimidine showed only mild adverse events, similar to previous studies.38, 41 387 
Moderate, severe and serious adverse events were observed in the mefloquine 388 
and mefloquine-artesunate treatment groups 24 hours after drug administration. 389 
Vertigo, dizziness and nausea were the most common adverse events reported. 390 
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All seriously affected patients were referred to the provincial hospital and 391 
provided appropriate medical care. Most of the patients recovered and were 392 
discharged from the hospital a day later. Surprisingly, patients in our current 393 
study were more likely to experience adverse events than observed in S. 394 
haematobium infected school-children in Côte d’Ivoire treated with mefloquine 395 
and mefloquine-artesunate.17 Only mild and transient adverse events were 396 
observed in the latter study, with abdominal pain the most frequent adverse event 397 
reported.17 We cannot explain at the moment why mefloquine and mefloquine-398 
artesunate were not tolerated in our study population, but the O. viverrini infection 399 
and other host factors might play a role.  400 
In conclusion, tribendimidine showed a promising activity against 401 
O. viverrini in our study. The nematocidal and opisthorchicidal properties of this 402 
drug are very intriguing as there is huge geographical overlap of these parasites 403 
and preventive chemotherapy is the mainstay of control. Once all preclinical 404 
studies have been completed to register the drug outside China large scale 405 
clinical studies should be conducted in O. viverrini endemic settings. 406 
Furthermore, it is interesting that in contrast to in vivo studies, antimalarial drugs 407 
are ineffective in the treatment of O. viverrini infections. Nonetheless, the 408 
deployment of antimalarials in areas of malaria-liver fluke coinfections might have 409 
marginal benefits as these drugs have been shown to slightly reduce O. viverrini 410 
egg counts. In addition, it might be of interest to study tribendimidine-praziquantel 411 
combinations in O. viverrini infected hamsters, as recently done in Clonorchis 412 
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sinensis infected rats,42 since combination chemotherapy is a useful strategy to 413 
delay the emergence of drug resistance. 414 
 21 
What this study adds: 
           Tribendimidine at recommended doses for the treatment of soil-
transmitted helminths infections achieved high cure and egg reduction 
rates in secondary school children infected with Opisthorchis viverrini  
           No or only very moderate effects were observed with mefloquine, 
artesunate and mefloquine-artesunate against O. viverrini 
           Frequent adverse events, many of which were serious were observed 
following treatment with mefloquine, and mefloquine-artesunate. Only mild 
and transient adverse events were observed in secondary school children 
treated with tribendimidine 
 415 
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Assessed for eligibility 
(n=197) 
Eligibility O. viverrini infected children  
(n=197) 
Enrollment 
Excluded (n=72): 
 Provided only single stool sample (n=70) 
 Fever (n=1) 
 Splenomegaly (n=1) 
Randomization 
(n=125) 
Mefloquine 
(n=25) 
Artesunate 
(n=24) 
Mefloquine-artesunate 
(n=24) 
Tribendimidine 
(n=27) 
Praziquantel 
(n=25) 
Lost to follow-up 
(n=7) 
Lost to follow-up 
(n=3) 
Lost to follow-up 
(n=0) 
Lost to follow-up 
(n=6) 
Lost to follow-up 
(n=3) 
Analysis 
(n=19) 
Analysis 
(n=24) 
Analysis 
(n=17) 
Analysis 
(n=24) 
Analysis 
(n=22) 
Follow-up 
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Table 1. Demographic and laboratory baseline characteristics of 125 schoolchildren infected with Opisthorchis viverrini at inclusion 
 
 Drugs 
Parameters Mefloquine Artesunate Mefloquine-artesunate Tribendimidine Praziquantel 
 (n = 25) (n = 24) (n = 24) (n = 27) (n = 25) 
Characteristics      
Boys/girls 16/9 13/11 12/12 10/17 12/13 
Mean (±SD) age, years 13.4 (1.2) 13.3 (1.6) 13.4 (1.6) 13.3 (1.3) 13.6 (1.3) 
Mean (±SD) weight, kg 39.5 (5.4) 38.8 (6.8) 38.0 (6.3) 40.6 (7.0) 39.4 (5.6) 
Parasite infections      
Opisthorchis viverrini infection
 a
        
Overall GM epg 
GM epg (range) 
1159.7 
(609.1- 2208.0) 
1368.0  
(745.3- 2510.9) 
1207.8  
(715.1-2040.0) 
1968.1  
(988.7 -3917.7) 
1925.4  
(970.2-3821.2) 
 No of light infection (1-999 epg)  14 (56.0) 11 (45.8) 11 (45.8) 9 (33.3) 11(44.0) 
No of moderate infection (1000- 9999 epg)  9 (36.0) 12 (50.0) 11 (45.8) 14 (51.9) 9 (36.0) 
No of heavy infection (>10 000 epg) 2 (8.0) 1 (4.2) 2 ( 8.3) 4 (14.8) 5(20.0) 
Co-infection with  soil-transmitted helminths      
Hookworm 19 (76.0) 20 (83.3) 17 (70.8) 20 (74.1) 20 (80.0) 
Ascaris lumbricoides 0 (0) 0 (0) 0 (0) 3 (11.1) 4 (16.0) 
Trichuris trichiura 1 (4.0) 1 (4.2) 0 (0) 1 (3.7) 0 (0) 
Taenia spp 2 (8.0) 1 (4.2) 1 (4.2) 1 (3.7) 3 (12.0) 
  a  According to guideline’s classification put forward by WHO, based on Kato-Katz analysis; Data are no; (%) of subject, otherwise indicated (95% confident interval); GM, geometric mean; 
epg, eggs per gram of stool 
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Table 2. Prevalence and cure rate of mefloquine, artesunate, mefloquine-artesunate, tribendimidine and praziquantel schoolchildren infected with Opisthorchis viverrini at 
follow-up 
 Intention-to-treat analysis 
Mefloquine 
(n = 25) 
Artesunate 
(n = 24) 
Mefloquine-artesunate 
(n = 24) 
Tribendimidine 
(n = 27) 
Praziquantel 
(n = 25) 
Kato-Katz thick smear technique      
Opisthorchis viverrini      
No. of patients cured (%)  0 (0)  1 (4.2) 1 (4.2) 19 (70.4) 14 (56.0) 
GM epg (range) 1052.2 (537.8- 2058.4) 1229.4 (625.1-2417.7) 653.9 (323.9-1320.1) 578.5 (47.7-7009.5) 159.9 (38.1- 671.2) 
ERR (%) 30.2  31.5 41.3 99.3 98.4  
Co-infection with hookworm      
No. of patients of sole hookworm infection (n = 86) (n = 17) (n = 20) (n = 15) (n = 17) (n = 17) 
No. of patients cured (%) 
 
3 (17.7) 4 (20.0) 
 
3 (20.0) 11 (64.7) 2 (11.8) 
 
 Per-protocol analysis 
 Mefloquine 
(n = 19) 
Artesunate 
(n = 24) 
Mefloquine-artesunate 
(n = 17) 
Tribendimidine 
(n = 24) 
Praziquantel 
(n = 22) 
Kato-Katz thick smear technique      
Opisthorchis viverrini      
No. of patients cured (%) 0 (0) 1 (4.2) 1 (6.0) 19 (79.2) 14 (63.6) 
GM epg (range)  1114.1 (498.9-2488.1) 1229.4 (625.1-2417.7) 669.1 (320.8-1395.7) 44.7 (11.6-171.7)  43.1 (16.6-111.7) 
ERR (%) 28.7 31.5 36.6 99.3 98.4 
Co-infection with hookworm      
No. patients of sole hookworm infection (n = 81) (n = 15) (n = 20) (n = 12) (n = 17) (n = 17) 
No. of patients cured (%) 3 (20.0) 4 (20.0) 2 (16.7) 11 (65.0) 2 (13.0) 
FECT technique      
Opisthorchis viverrini      
No. of patients cured (%) 4 (21.1) 8 (33.3) 8 (47.1)  23 (95.8) 21 (95.5) 
GM epg (range) 182.3 (77.0-433.5) 156.2 (82.2-297.0) 114.0 (69.2-187.3) na na 
ERR (%) 71.0 60.0 75.0 99.1 99.0 
Note. Data are no; (%) of subject, otherwise indicated (95% confident interval); GM, geometric mean; epg, eggs per gram of stool; ERR, egg reduction rate; ; na, not applicable 
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Table 3. Comparison of treatment outcome between groups 
 Intention-to-treat analysis 
 MQ vs PZQ P AS vs PZQ P MQ-AS vs PZQ P TBD vs PZQ P 
Kato-Katz thick smear technique         
Opisthorchis viverrini         
OR na na 0.03 (0.004-0.29) 0.002 0.03 (0.004-0.29) 0.002 1.87 (0.60-5.85) 0.29 
ERRR 0.40 (0.21-0.72) 0.003 0.43 (0.23 – 0.80) 0.008 0.60 (0.31-1.10) 0.08 1.00 (0.44-2.30) 0.98 
Co-infection with hookworm         
                             OR 1.61 (0.23-11.09) 0.63 1.88 (0.30-11.78) 0.50 1.88 (0.27- 13.09) 0.52 13.75 (2.32-81.49) 0.004 
 Per-protocol analysis 
 MQ vs PZQ P AS vs PZQ P MQ-AS vs PZQ P TBD vs PZQ P 
Kato-Katz thick smear technique         
Opisthorchis viverrini         
OR na na   0.02 (0.003-0.22) 0.001 0.04 (0.004-0.32) 0.003 2.17 (0.58-8.08) 0.25 
ERRR 0.36 (0.19-0.68) 0.002 0.42 (0.22 -0.80)
 
 0.008 0.54 (0.28-1.03)  0.06 1.00 (0.44-2.31)
 
 0.98  
Co-infection with hookworm         
OR 1.88 (0.27-13.09) 0.53 1.88 (0.30-11.78) 0.50 1.50 (0.18-12.46) 0.70 13.75 (2.32-81.49) 0.004 
FECT technique         
OR 0.01 (0.001-0.13) <0.001 0.02 (0.003-0.21) 0.001 0.04 (0.005-0.39) 0.005 1.10 (0.06-18.64) 0.95 
ERRR 0.54 (0.43-0.67) <0.001 0.81 (0.70-0.94) 0.009 0.87 (0.72-1.04) 0.14 1.00 (0.86-1.16) 0.99 
Note. Data are odds ratios (OR, 95% confidence intervals) of parasite clearance; ERRR, egg reduction rate ratio; na, not applicable; MQ: mefloquine; AS: artesunate; MQ-AS Mefloquine-
artesunate; TBD tribendimidine; PZQ Praziquantel 
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Table 4.1 Clinical symptoms reported 3-48 hour after drug administration among 125 schoolchildren, stratified by treatment group 
 No, (%) individuals with adverse event  
 Mefloquine Artesunate Mefloquine-artesunate Tribendimidine Praziquantel 
 (n = 25) (n = 24) (n = 24) (n = 27) (n = 25) 
Adverse event / 
Grade 
3 24 48 
At any 
time point 
3 24 48 
At any 
Time point 
3 24 48 
At any 
time point 
3 24 48 
At any 
time point 
3 24 48 
At any 
time point 
Fatigue                      
Mild  3 4 2 7 (28.0) 2 3 2 6 (25.0) 4 5 7 12 (50.0) 2 3 2 5 (18.5) 5 8 2 11 (44.0) 
Moderate 0 0 3 3 (12.0) 0 1 1 2 (8.3) 3 1 2 5 (20.8) 0 0 0 0 0 0 0 0 
Severe 0 0 2 2 (8.0) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Serious 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Asthenia                     
Mild  0 4 0 4 (16.0) 0 2 0 2 (8.3) 0 4 0 2 (8.3) 0 1 1 1 (3.7) 0 0 1 1 (4.0) 
Moderate 0 6 0 6 (24.0) 0 1 0 1 (4.2) 0 3 0 3 (12.5) 0 0 0 0 0 0 0 0 
Severe 0 8 0 8 (32.0)  0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 (4.0) 
Serious 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Headache                     
Mild  4 3 2 7 (28.0) 6 8 2 12 (50.0) 6 9 6 14 (58.3) 4 10 1 12 (44.4) 12 7 2 16 (64.0) 
Moderate 1 2 4 6 (24.0) 1 2 1 4 (16.7) 1 3 4 8 (33.3) 0 0 0 0 0 2 0 2 (8.0) 
Severe 0 1 3 3 (12.0) 0 1 0 1 (4.2) 1 1 1 1 (4.2) 0 0 0 0 0 2 0 2 (8.0) 
Serious 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Vertigo                     
Mild  6 3 1 9 (36.0)
 a
 3 5 1 7 (29.2) 3 8 6 12 (50.0) 4 6 0 9 (33.4) 11 8 2 16 (64.0) 
Moderate 1 13 4 15 (60.0) 1 0 0 1 (4.2) 1 7 4 10 (41.7) 0 1 1 1 (3.7) 0 2 0 2 (8.0) 
Severe 0 0 3 3 (12.0) 0 1 0 1 (4.2) 1 1 0 1 (4.2) 0 0 0 0 0 0 0 0 
Serious 0 1 1 1 (4.0) 0 0 0 0  0 1 0 1 (4.2) 0  0 0 0 0 0 0 
Vomiting                     
Mild  0 1 0 1 (4.0) 0 1 0 1 (4.2) 0 2 3 4 (16.7) 0 1 1 1 (3.7) 0 2 1 2 (8.0) 
Moderate 0 7 6 10 (40.0) 0 0 0 0 0 3 1 3 (12.5) 0 0 0 0 0 1 1 1 (4.0) 
Severe 0 6 1 6 (24.0) 0 0 0 0 0 5 2 6 (25.0) 0 0 0 0 0 0 0 0 
Serious 0 5 0 5 (20.0) 0 0 0 0 0 4 0 4 (16.7) 0 0 0 0 0 0 0 0 
Nausea                     
Mild  2 4 1 6 (24.0) 2 3 2 5 (20.8) 7 6 6 14 (58.3) 3 7 0 9 (33.3) 5 5 1 10 (40.0) 
Moderate 1 8 5 11 (44.0)
 b
 0 0 1 1 (4.2) 0 5 3  8 (33.3) 1 0 1 2 (7.4) 1 0 1 2 (8.0) 
Severe 0 2 1 2 (8.0) 0 0 0 0 0 3 0 3 (12.5) 0 0 0 0 0 0 0 0 
Serious 0 2 1 2 (8.0) 0 0 0 0 0 2 0 2 (8.3) 0 0 0 0 0 0 0 0 
a 
Significantly different from PQZ-treated children (p< .02); 
b 
Significantly different from PQZ-treated children (p< .007); 
c 
Significantly different from PQZ-treated children (p< .001) 
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Table 4.2 Clinical symptoms reported 3-48 hour after drug administration among 125 schoolchildren, stratified by treatment group  
 No, (%) individuals with adverse event  
 Mefloquine Artesunate Mefloquine-artesunate Tribendimidine Praziquantel 
 (n = 25) (n = 24) (n = 24) (n = 27) (n = 25) 
Adverse event / 
Grade 
3 24 48 
At any 
time point 
3 24 48 
At any 
Time point 
3 24 48 
At any 
time point 
3 24 48 
At any 
time point 
3 24 48 
At any 
time point 
Abdominal pain                     
Mild  0 0 0 0 0 1 1 1 (4.2) 0 4 0 4 (16.7) 0 1 0 1 (3.7) 0 2 0 2 (8.0) 
Moderate 0 0 0 0 0 0 0 0 0 1 0 1 (4.2) 0 0 0 0 0 0 0 0 
Severe 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Serious 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Dizziness                     
Mild  0 0 0 0 0 0 1 1 (4.2) 0 1 0 1 (4.2) 0 1 1 1 (3.7) 0 2 0 2 (8.0) 
Moderate 0 12 0 12 (48.0) 
a
 0 0 0 0 0 7 0 7 (29.2) 
c
 0 0 0 0 0 1 0 1 (4.0) 
Severe 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Serious 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Somnolence                     
Mild 0 0 1 1 (4.0) 0 1 0 1 (4.2) 0 0 3 3 (12.5) 0 1 1 1 (3.7) 0 2 1 2 (8.0) 
Moderate 0 0 1 1 (4.0) 0 1 0 1 (4.2) 0 0 0 0 0 0 0 0 0 0 0 0 
Severe 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Serious 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Anxiety                     
Mild 0 1 0 1 (4.0) 0 2 1 2 (8.3) 0 1 2 2 (8.3) 0 1 1 1 (3.7) 0 0 1 1 (4.0) 
Moderate 0 1 0 1 (4.0) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Severe 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Serious 0 0 0 0 0 0 0 0 0 1 0 1 (4.2) 0 0 0 0 0 0 0 0 
Insomnia                     
       Mild 0 2 0 2 (8.0) 0 1 0 1 (4.2) 0 0 0 0 0 0 0 0 0 0 0 0 
       Moderate 0 2 0 2 (8.0) 0 0 0 0 0 1 0 1 (4.2) 0 0 0 0 0 0 0 0 
Severe 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Serious 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
a 
Significantly different from PQZ-treated children (p< .02); 
b 
Significantly different from PQZ-treated children (p< .007); 
c 
Significantly different from PQZ-treated children (p< .001) 
 37 
 
Table 5.  Summary of clinical symptoms recorded at 3-48 hour after drug administration, stratified by treatment group 
 
 Treatment group  
Adverse event arisen after 
treatment  
Mefloquine  
 (n =25 ) 
Artesunate  
(n =24 ) 
Mefloquine-artesunate  
(n =24 ) 
Tribendimidine  
(n =27 ) 
Praziquantel  
(n =25 ) 
Total 
(n=125) 
At least 1 adverse event 22 (88.0) 16 (66.7) 23 (95.8) 20 (74.1) 20 (80.0) 101 (80.8) 
Mild 18 (72.0) 15 (62.5) 20 (83.3) 19 (70.4) 20 (80.0) 92 ( 73.6) 
Moderate 19 (76.0)  5 (20.8)  16 (66.7)  2 (7.4) 5 (20.0) 47 (37.6)
 
 
Severe 12 (48.0)
 
 2 (8.3) 4 (16.7)
 
 1 (3.7) 4 (16.0) 23 (18.4) 
Serious 4 (8.3) 0 8 (33.3) 0(0) 0(0) 12 (9.6) 
